Physician profile
Cory D Cross
NPI 1104966290
$2,958.87
in general payments reported to CMS, 2019-2025
24 companies · $115 in 2025
The $115 reported for 2025 was less than what a typical Sleep Medicine (Internal Medicine) provider received nationally (typical 2025 total: $447).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,871 · 2020: $223 · 2021: $750 · 2025: $115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $99.99 · Food and Beverage: $14.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $99.99 |
| Food and Beverage | $14.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $794.28 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $295.01 | 2019-2020 | |
| Gilead Sciences, INC. | $268.41 | 2019 | |
| Allergan, INC. | $217.78 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $198.06 | 2019-2020 | |
| Genentech USA, INC. | $181.92 | 2019-2020 | |
| Glaxosmithkline, LLC. | $174.62 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $137.36 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $136.78 | 2019 | |
| Harmony Biosciences LLC | $99.99 | 2025 | |
| Jazz Pharmaceuticals INC. | $62.55 | 2019 | |
| Merck Sharp & Dohme LLC | $57.55 | 2019-2020 | |
| United Therapeutics Corporation | $54.21 | 2019 | |
| Vifor Pharma, INC. | $53.74 | 2019 | |
| Novartis Pharmaceuticals Corporation | $43.20 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Portola Pharmaceuticals, LLC | $33.91 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $31.22 | 2019 | |
| Janssen Pharmaceuticals, INC | $22.26 | 2019 | |
| Insmed, INC. | $19.58 | 2020 | |
| Edwards Lifesciences Corporation | $18.22 | 2019 | |
| Paratek Pharmaceuticals, INC. | $17.62 | 2020 | |
| Amgen INC. | $14.75 | 2025 | Tezspire |
| Mallinckrodt Enterprises LLC | $13.24 | 2019 | |
| Electromed, INC. | $12.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cory Cross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.